Cutaneous squamous cell carcinoma market trends influencing growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market Progress Between 2026 And 2030?
The cutaneous squamous cell carcinoma (cscc) market has experienced substantial growth in recent years. It is projected to expand from $7.87 billion in 2025 to $8.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be primarily attributed to high UV exposure rates, an increasing aging population, enhanced skin cancer awareness, the prevalence of surgical excision, and hospital-based oncology care.
The cutaneous squamous cell carcinoma (cscc) market is anticipated to show significant expansion in the coming years, with its value projected to reach $10.35 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This upward trajectory during the forecast period is fueled by advancements in skin cancer diagnostics, a growing preference for outpatient procedures, the proliferation of dermatologic oncology centers, enhanced access to early detection methods, and the ongoing development of targeted therapies. Prominent trends expected in this timeframe include the increasing adoption of Mohs micrographic surgery, a rise in non-surgical treatment options, broader early skin cancer screening initiatives, the expansion of outpatient cancer care facilities, and a sustained focus on minimally invasive medical procedures.
Access Your Free Sample Report For In-Depth Market Analysis:
What Significant Factors Are Influencing The Cutaneous Squamous Cell Carcinoma (cSCC) Market Expansion?
Increased understanding of skin cancer is expected to drive the expansion of the cutaneous squamous cell carcinoma (cSCC) market in the future. Skin cancer involves the irregular proliferation of skin cells, frequently triggered by excessive UV exposure, with outcomes varying from harmless to life-threatening. This heightened awareness stems from expanded public health campaigns, easier access to information, and a stronger focus on prompt diagnosis and preventative measures, resulting in increased need for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) contributes significantly to progress in skin cancer care through facilitating targeted therapies, refining diagnostic processes, and improving patient results, thereby promoting superior disease management. As an illustration, in January 2024, data from the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, indicated 104,930 reported cases of skin cancer in 2023, which represents a 3.2% increase from the 108,270 cases documented in 2022. Consequently, the increasing awareness of skin cancer will stimulate growth within the cutaneous squamous cell carcinoma (cSCC) market.
What Are The Different Segment Types In The Cutaneous Squamous Cell Carcinoma (cSCC) Market Segment Breakdown?
The cutaneous squamous cell carcinoma (cscc) market covered in this report is segmented –
1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
What Trends Are Affecting The Direction Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
Major companies within the cutaneous squamous cell carcinoma (cSCC) market are prioritizing developments in immuno-oncology therapies, such as PD-L1 inhibitors and targeted treatments, to enhance patient outcomes and offer effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that suppresses the immune response by binding to PD-1 receptors on T-cells, assisting cancer cells in evading detection by the immune system. As an illustration, in December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, obtained FDA approval for Unloxcyt (cosibelimab-ipdl). The innovation of this product resides in its capacity to block PD-L1, thereby boosting the immune system’s ability to combat cancer while providing a safer and more efficacious treatment option. Additionally, its dual mechanisms of action present a promising strategy for addressing advanced cutaneous squamous cell carcinoma (cSCC). This approval was founded on results from the CK-301-101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients suffering from advanced cSCC.
Who Are The Well-Known Companies In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
Major companies operating in the cutaneous squamous cell carcinoma (cscc) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., Vidac Pharma Inc., Pfizer Inc., AstraZeneca plc, AbbVie Inc., Johnson & Johnson, Bayer AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd.
Get The Full Cutaneous Squamous Cell Carcinoma (cSCC) Market Report:
Which Geographic Region Dominates The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (cscc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cutaneous Squamous Cell Carcinoma (cSCC) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cutaneous Squamous Cell Carcinoma (cSCC) Market 2026, By The Business Research Company
Skin Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report
Basal Cell Carcinoma Treatment Market Report 2026
Non Small Cell Lung Cancer Nsclc Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
